Ultragenyx Pharmaceutical (RARE) Income from Continuing Operations (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Income from Continuing Operations of 185000000.0 for Q1 2026, down 22.52% year-over-year from 238760683.76 in Q1 2025, and down 50.95% quarter-over-quarter from 122556000.0 in Q4 2025.
Powered by 
Analysis
Ultragenyx Pharmaceutical (RARE) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Income from Continuing Operations for 14 consecutive years, with 185000000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 22.52% year-over-year to 185000000.0; the TTM figure through Mar 2026 stood at 602920000.0 (down 10.56% YoY), while the FY2025 annual figure was 569000000.0, down 0.71% from the prior year.
- Income from Continuing Operations fell to 185000000.0 in Q1 2026 per RARE's latest filing, from 122556000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 114951000.0 in Q2 2025 and bottomed at 245106000.0 in Q3 2022.
- Historically, Income from Continuing Operations has averaged 154998882.35 across 5 years, with a median of 153473000.0 in 2022.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 235.77% — and 2023, when it jumped 34.87%.
- Ultragenyx Pharmaceutical's Income from Continuing Operations stood at 153473000.0 in 2022, then advanced by 19.5% to 123551000.0 in 2023, then decreased by 4.57% to 129202000.0 in 2024, then rose by 5.14% to 122556000.0 in 2025, then slumped by 50.95% to 185000000.0 in 2026.
- Business Quant data shows RARE's Income from Continuing Operations at 185000000.0 in Q1 2026, 122556000.0 in Q4 2025, and 180413000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Ultragenyx Pharmaceutical | 1.56 Bn | 1.27 Bn | 180.00 Mn | -92.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -92.00 Mn |
| Mar 31, 2026 | -185.00 Mn |
| Dec 31, 2025 | -4.56 Mn |
| Sep 30, 2025 | -180.41 Mn |
| Jun 30, 2025 | -115.00 Mn |
| Mar 31, 2025 | -151.00 Mn |
| Dec 31, 2024 | -134.20 Mn |
| Sep 30, 2024 | -133.52 Mn |
| Jun 30, 2024 | -131.60 Mn |
| Mar 31, 2024 | -170.68 Mn |
| Dec 31, 2023 | -123.55 Mn |
| Sep 30, 2023 | -159.65 Mn |
| Jun 30, 2023 | -159.83 Mn |
| Mar 31, 2023 | -163.97 Mn |
| Dec 31, 2022 | -155.16 Mn |
| Sep 30, 2022 | -245.11 Mn |
| Jun 30, 2022 | -158.16 Mn |
| Mar 31, 2022 | -152.32 Mn |
| Dec 31, 2021 | -124.79 Mn |
| Sep 30, 2021 | -73.00 Mn |